EXTENDED REPORT

¹ University Hospital Maastricht, Maastricht, The Netherlands
² Hospital Garcia de Orta, Almado, Portugal
³ Cochin Hospital, Paris, France
⁴ Hospitaller Brothers of St John of God, Budapest, Hungary
⁵ VU University Medical Center, Amsterdam, The Netherlands
⁶ Universitari de Bellvitge, Idibell, Spain
⁷ San Carlo Hospital, Potenza, Italy
⁸ Jan Palfijn Hospital, Merksem, Belgium
⁹ AHEPA Hospital, University of Thessaloniki, Thessaloniki, Greece
¹⁰ Free University, Berlin, Germany
¹¹ Wroclaw University of Medicine, Wroclaw, Poland
¹² Freeman Hospital, Newcastle upon Tyne, UK
¹³ Wyeth Research, Paris, France
¹⁴ Wyeth Research, Collegeville, Pennsylvania, USA

Correspondence to:
J S Wajdula
Clinical Research and Development, Wyeth Research, 500 Arcola Road, Collegeville, PA 19426, USA;wajdulj{at}wyeth.com

Objective: To compare the efficacy, pharmacokinetics and safety of etanercept 50 mg once weekly with 25 mg twice weekly and placebo in patients with ankylosing spondylitis.

Methods: A 12-week, double-blind, placebo-controlled study compared the effects of etanercept 50 mg once weekly, etanercept 25 mg twice weekly and placebo in 356 patients with active ankylosing spondylitis (3:3:1 randomisation, respectively). The primary end point was the proportion of patients achieving a response at week 12 based on the Assessment in Ankylosing Spondylitis Working Group criteria (ASAS 20). The pharmacokinetics of etanercept 50 mg once weekly and 25 mg twice weekly were analysed.

Results: Baseline characteristics and disease activity were similar among the three groups: etanercept 50 mg once weekly, etanercept 25 mg twice weekly and placebo. The percentage of patients discontinuing therapy was 9.0%, 9.3% and 13.7% for the three respective groups. ASAS 20 response at 12 weeks was achieved by 74.2% of patients with etanercept 50 mg once weekly and 71.3% of those with etanercept 25 mg twice weekly, both significantly higher than the percentage of patients taking placebo (37.3%, p<0.001). Percentages of patients with ASAS 5/6 response (70.3%, 72.0% and 27.5%, respectively; p<0.001) and those with ASAS 40 response (58.1%, 53.3% and 21.6%, respectively; p<0.001) followed a similar pattern. Significant improvement (p<0.05) was seen in measures of disease activity, back pain, morning stiffness and C reactive protein levels as early as 2 weeks. Serum etanercept exposure was similar between the etanercept groups. Incidence of treatment-emergent adverse events, including infections, was similar among all three groups, and no unexpected safety issues were identified.

Conclusions: Patients with ankylosing spondylitis can expect a comparable significant improvement in clinical outcomes with similar safety when treated with etanercept 50 mg once weekly or with 25 mg twice weekly.

Abbreviations: ASAS, Assessment in Ankylosing Spondylitis; AUC, area under the curve; BASDAI, Bath Ankylosing Spondylitis Disease Activities Index; CRP, C reactive protein; NCI, National Cancer Institute; TNF, tumour necrosis factor; VAS, visual analogue scale

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• KOIKE, T., HARIGAI, M., INOKUMA, S., INOUE, K., ISHIGURO, N., RYU, J., TAKEUCHI, T., TANAKA, Y., YAMANAKA, H., FUJII, K., FREUNDLICH, B., SUZUKAWA, M. (2009). Postmarketing Surveillance of the Safety and Effectiveness of Etanercept in Japan. The Journal of Rheumatology 36: 898-906 [Abstract] [Full Text]  
• Yazici, Y., Adler, N. M., Yazici, H. (2008). Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations. Rheumatology (Oxford) 47: 1054-1057 [Abstract] [Full Text]  
• Braun, J., McHugh, N., Singh, A., Wajdula, J. S., Sato, R. (2007). Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology (Oxford) 46: 999-1004 [Abstract] [Full Text]  
• Prince, F. H M, Twilt, M., Jansen-Wijngaarden, N. C J A, van Suijlekom-Smit, L. W A (2007). Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical study. Ann Rheum Dis 66: 704-705 [Full Text]